Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters

Christopher P. Landowski, Duxin Sun, David R. Foster, Sujatha S. Menon, Jeffrey L. Barnett, Lynda S. Welage, Chandrasekharan Ramachandran, Gordon L. Amidon

Research output: Contribution to journalArticleScientificpeer-review

79 Citations (Scopus)

Abstract

The transport of valacyclovir, the L-valyl ester of acyclovir, has been suggested to be mediated by several carrier-mediated pathways in cell culture and animal models. The role and importance of these transporters in modulating valacyclovir absorption in humans has not been determined, however. Recent advances in genomic technology have facilitated the rapid and simultaneous determination of global mRNA expression profiles for thousands of genes in tissue biopsies directly associated with the absorption process, thereby dramatically increasing the value of studies in humans. In this article, we describe correlations of pharmacokinetic parameters following oral valacyclovir or acyclovir administration with expression levels of intestinal genes in humans. Highly positive and significant correlations were observed with 4F2hc, an activator of cation-preferring amino acid transport systems, and human oligopeptide transporter (HPT1), an oligopeptide transporter expressed at higher levels in the human intestine compared with oligopeptide transporter (PEPT1). The validation of HPT1 microarray data with reverse transcription-polymerase chain reaction and the enhanced valacyclovir uptake in HeLa/HPT1 cells suggest that the role of HPT1 in transport of peptides and peptidomimetics drugs needs to be examined in more detail. The interrelation of 4F2hc and HPT1 in transport may be of interest. No significant correlations of valacyclovir pharmacokinetic parameters with PEPT1 and with organic cation or anion transporter expression levels were observed. The highly negative correlations observed with known efflux pumps such as MDR1 (P-glycoprotein) and MRP2 (cMOAT), as well as with the CYP450 IIIA subfamily may indicate that these proteins may regulate the cellular accumulation and metabolism of acyclovir.

Original languageEnglish
Pages (from-to)778-786
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume306
Issue number2
DOIs
Publication statusPublished - 1 Aug 2003
MoE publication typeA1 Journal article-refereed

Fingerprint

valacyclovir
Intestines
Pharmacokinetics
Gene Expression
Oligopeptides
Acyclovir
Cations
Peptidomimetics
Amino Acid Transport Systems
P-Glycoprotein
HeLa Cells
Transcriptome
Reverse Transcription
Anions
Animal Models
Cell Culture Techniques

Cite this

Landowski, Christopher P. ; Sun, Duxin ; Foster, David R. ; Menon, Sujatha S. ; Barnett, Jeffrey L. ; Welage, Lynda S. ; Ramachandran, Chandrasekharan ; Amidon, Gordon L. / Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. In: Journal of Pharmacology and Experimental Therapeutics. 2003 ; Vol. 306, No. 2. pp. 778-786.
@article{a44371b3ffad4446831f7b34a0867a47,
title = "Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters",
abstract = "The transport of valacyclovir, the L-valyl ester of acyclovir, has been suggested to be mediated by several carrier-mediated pathways in cell culture and animal models. The role and importance of these transporters in modulating valacyclovir absorption in humans has not been determined, however. Recent advances in genomic technology have facilitated the rapid and simultaneous determination of global mRNA expression profiles for thousands of genes in tissue biopsies directly associated with the absorption process, thereby dramatically increasing the value of studies in humans. In this article, we describe correlations of pharmacokinetic parameters following oral valacyclovir or acyclovir administration with expression levels of intestinal genes in humans. Highly positive and significant correlations were observed with 4F2hc, an activator of cation-preferring amino acid transport systems, and human oligopeptide transporter (HPT1), an oligopeptide transporter expressed at higher levels in the human intestine compared with oligopeptide transporter (PEPT1). The validation of HPT1 microarray data with reverse transcription-polymerase chain reaction and the enhanced valacyclovir uptake in HeLa/HPT1 cells suggest that the role of HPT1 in transport of peptides and peptidomimetics drugs needs to be examined in more detail. The interrelation of 4F2hc and HPT1 in transport may be of interest. No significant correlations of valacyclovir pharmacokinetic parameters with PEPT1 and with organic cation or anion transporter expression levels were observed. The highly negative correlations observed with known efflux pumps such as MDR1 (P-glycoprotein) and MRP2 (cMOAT), as well as with the CYP450 IIIA subfamily may indicate that these proteins may regulate the cellular accumulation and metabolism of acyclovir.",
author = "Landowski, {Christopher P.} and Duxin Sun and Foster, {David R.} and Menon, {Sujatha S.} and Barnett, {Jeffrey L.} and Welage, {Lynda S.} and Chandrasekharan Ramachandran and Amidon, {Gordon L.}",
year = "2003",
month = "8",
day = "1",
doi = "10.1124/jpet.103.051011",
language = "English",
volume = "306",
pages = "778--786",
journal = "The Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. / Landowski, Christopher P.; Sun, Duxin; Foster, David R.; Menon, Sujatha S.; Barnett, Jeffrey L.; Welage, Lynda S.; Ramachandran, Chandrasekharan; Amidon, Gordon L.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 306, No. 2, 01.08.2003, p. 778-786.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters

AU - Landowski, Christopher P.

AU - Sun, Duxin

AU - Foster, David R.

AU - Menon, Sujatha S.

AU - Barnett, Jeffrey L.

AU - Welage, Lynda S.

AU - Ramachandran, Chandrasekharan

AU - Amidon, Gordon L.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - The transport of valacyclovir, the L-valyl ester of acyclovir, has been suggested to be mediated by several carrier-mediated pathways in cell culture and animal models. The role and importance of these transporters in modulating valacyclovir absorption in humans has not been determined, however. Recent advances in genomic technology have facilitated the rapid and simultaneous determination of global mRNA expression profiles for thousands of genes in tissue biopsies directly associated with the absorption process, thereby dramatically increasing the value of studies in humans. In this article, we describe correlations of pharmacokinetic parameters following oral valacyclovir or acyclovir administration with expression levels of intestinal genes in humans. Highly positive and significant correlations were observed with 4F2hc, an activator of cation-preferring amino acid transport systems, and human oligopeptide transporter (HPT1), an oligopeptide transporter expressed at higher levels in the human intestine compared with oligopeptide transporter (PEPT1). The validation of HPT1 microarray data with reverse transcription-polymerase chain reaction and the enhanced valacyclovir uptake in HeLa/HPT1 cells suggest that the role of HPT1 in transport of peptides and peptidomimetics drugs needs to be examined in more detail. The interrelation of 4F2hc and HPT1 in transport may be of interest. No significant correlations of valacyclovir pharmacokinetic parameters with PEPT1 and with organic cation or anion transporter expression levels were observed. The highly negative correlations observed with known efflux pumps such as MDR1 (P-glycoprotein) and MRP2 (cMOAT), as well as with the CYP450 IIIA subfamily may indicate that these proteins may regulate the cellular accumulation and metabolism of acyclovir.

AB - The transport of valacyclovir, the L-valyl ester of acyclovir, has been suggested to be mediated by several carrier-mediated pathways in cell culture and animal models. The role and importance of these transporters in modulating valacyclovir absorption in humans has not been determined, however. Recent advances in genomic technology have facilitated the rapid and simultaneous determination of global mRNA expression profiles for thousands of genes in tissue biopsies directly associated with the absorption process, thereby dramatically increasing the value of studies in humans. In this article, we describe correlations of pharmacokinetic parameters following oral valacyclovir or acyclovir administration with expression levels of intestinal genes in humans. Highly positive and significant correlations were observed with 4F2hc, an activator of cation-preferring amino acid transport systems, and human oligopeptide transporter (HPT1), an oligopeptide transporter expressed at higher levels in the human intestine compared with oligopeptide transporter (PEPT1). The validation of HPT1 microarray data with reverse transcription-polymerase chain reaction and the enhanced valacyclovir uptake in HeLa/HPT1 cells suggest that the role of HPT1 in transport of peptides and peptidomimetics drugs needs to be examined in more detail. The interrelation of 4F2hc and HPT1 in transport may be of interest. No significant correlations of valacyclovir pharmacokinetic parameters with PEPT1 and with organic cation or anion transporter expression levels were observed. The highly negative correlations observed with known efflux pumps such as MDR1 (P-glycoprotein) and MRP2 (cMOAT), as well as with the CYP450 IIIA subfamily may indicate that these proteins may regulate the cellular accumulation and metabolism of acyclovir.

UR - http://www.scopus.com/inward/record.url?scp=0038637117&partnerID=8YFLogxK

U2 - 10.1124/jpet.103.051011

DO - 10.1124/jpet.103.051011

M3 - Article

C2 - 12750437

AN - SCOPUS:0038637117

VL - 306

SP - 778

EP - 786

JO - The Journal of Pharmacology and Experimental Therapeutics

JF - The Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -